Dr. Andrew Poklepovic, MD
Claim this profileVirginia Commonwealth University/Massey Cancer Center
Expert in Cancer
Expert in Skin Cancer
36 reported clinical trials
85 drugs studied
Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Skin Cancer
Global LeaderStage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Andrew Poklepovic, MD is currently running
Immunotherapy + Chemotherapy
for Soft Tissue Sarcoma
This phase II trial compares the effect of immunotherapy with ipilimumab and nivolumab alone to their combination with cabozantinib in treating patients with soft tissue sarcoma that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply and may also prevent the growth of new blood vessels that tumors need to grow. By these actions it may help slow or stop the spread of cancer cells. Adding cabozantinib to the combination of ipilimumab and nivolumab may be better in stopping or slowing the growth of tumor compared to ipilimumab and nivolumab alone in patients with advanced soft tissue sarcoma.
Recruiting1 award Phase 2
Niraparib + Neratinib
for Ovarian Cancer
To determine the recommended phase 2 dose (RP2D) of niraparib and neratinib in combination in patients with advanced solid tumors during Phase 1. To evaluate clinical benefit (≥4-month progression-free survival \[PFS\]) of niraparib and neratinib in patients with platinum-resistant ovarian cancer in Phase 1b.
Recruiting1 award Phase 116 criteria
More about Andrew Poklepovic, MD
Clinical Trial Related5 years of experience running clinical trials · Led 36 trials as a Principal Investigator · 15 Active Clinical TrialsTreatments Andrew Poklepovic, MD has experience with
- Nivolumab
- Pembrolizumab
- Biospecimen Collection
- Ipilimumab
- Paclitaxel
- Ipatasertib
Breakdown of trials Andrew Poklepovic, MD has run
Cancer
Skin Cancer
Uterine Tumors
Melanoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Andrew Poklepovic, MD specialize in?
Andrew Poklepovic, MD focuses on Cancer and Skin Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Andrew Poklepovic, MD currently recruiting for clinical trials?
Yes, Andrew Poklepovic, MD is currently recruiting for 13 clinical trials in Richmond Virginia. If you're interested in participating, you should apply.
Are there any treatments that Andrew Poklepovic, MD has studied deeply?
Yes, Andrew Poklepovic, MD has studied treatments such as Nivolumab, Pembrolizumab, Biospecimen Collection.
What is the best way to schedule an appointment with Andrew Poklepovic, MD?
Apply for one of the trials that Andrew Poklepovic, MD is conducting.
What is the office address of Andrew Poklepovic, MD?
The office of Andrew Poklepovic, MD is located at: Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia 23298 United States. This is the address for their practice at the Virginia Commonwealth University/Massey Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.